From Hallelujah To Headwind: Pfizer's COVID-19 Franchise Hits The Downturn
Pfizer expects Comirnaty and Paxlovid revenues to be drastically lower this year after pushing 2022 revenues over $100bn. Management said 2023 would be a transition year for the company.
You may also be interested in...
If COVID-19 product sales don’t meet assumptions this fall, the company said it will consider a cost reduction program to better align costs with future revenue projections.
Data from the Phase III EMBARK study showed a significant improvement for the drug both in combination with leuprolide and as a monotherapy in reducing risk of metastasis or death in nmHSPC.
Pfizer and Astellas announced positive topline Phase III results in non-metastatic prostate cancer for Xtandi, one of the top-selling drugs in Pfizer’s portfolio set to lose patent exclusivity this decade.